医学
肺癌
临床试验
肿瘤微环境
免疫系统
放射治疗
肿瘤科
免疫
免疫检查点
免疫疗法
癌症研究
免疫学
内科学
作者
Peter H. Goff,Jing Zeng,Ramesh Rengan,Stephanie K. Schaub
标识
DOI:10.1016/j.semradonc.2020.11.010
摘要
Immune checkpoint inhibitors are approved for a variety of indications for locally advanced and metastatic non-small cell lung cancer (NSCLC), and trials are ongoing in the early-stage setting. There is an unmet need to understand which patients may derive benefit from immunotherapies and how to harness combined modality therapies to improve overall response rates and durability. Here, we review studies from the bench-to-bedside to examine the role of radiation therapy (RT) on the tumor immune microenvironment in NSCLC with an eye toward augmenting antitumor immunity. Together, these data provide a foundation for developing future clinical trials harnessing RT to augment antitumor immunity and highlight the need for correlative translational studies to directly characterize the impact of RT on the human NSCLC tumor immune microenvironment.
科研通智能强力驱动
Strongly Powered by AbleSci AI